See the DrugPatentWatch profile for Evkeeza
What is Evkeeza, and what does it treat?
Evkeeza is a prescription medicine (generic name: evinacumab) used to lower LDL cholesterol. It is used for certain people with familial hypercholesterolemia (including homozygous familial hypercholesterolemia) and other high-risk genetic lipid disorders, when LDL is not controlled enough with other treatments [1].
How does Evkeeza work?
Evinacumab is a monoclonal antibody that targets angiopoietin-like 3 (ANGPTL3). By inhibiting ANGPTL3, it helps the liver reduce the production of certain lipids and improves LDL cholesterol levels [1].
How is Evkeeza given?
Evkeeza is given as an intravenous (IV) infusion in a clinical setting (not as a pill) [1].
How quickly does it lower LDL cholesterol?
Clinical studies show LDL cholesterol reductions occur after starting treatment, with effects assessed over follow-up periods used in the trials. The exact timeline can vary by patient and dosing schedule [1].
What are the common side effects people ask about?
Side effects depend on the individual and the study population, but the most relevant considerations are those typical for IV monoclonal antibody therapy, including possible infusion-related reactions and other treatment-emergent effects reported in labeling [1].
Who should not take Evkeeza (or who needs extra caution)?
Use is based on the indication and clinical lipid profile, and patients should follow guidance in the official prescribing information for eligibility and precautions, including monitoring during infusion and attention to potential hypersensitivity/infusion reactions [1].
How does Evkeeza compare with other LDL-lowering drugs like statins or PCSK9 inhibitors?
Statins and PCSK9 inhibitors lower LDL cholesterol through different pathways than ANGPTL3 inhibition. Evkeeza is typically positioned for patients who need additional LDL lowering and/or who have genetic forms of high cholesterol where LDL levels remain high despite other therapies [1].
What happens if treatment is stopped?
If Evkeeza is discontinued, LDL cholesterol levels can rise again because the lipid-lowering effect from ANGPTL3 inhibition ends. Ongoing therapy decisions should be made with a clinician based on response and tolerability [1].
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761279